Sclerostin is involved in the regulation of osteoblastogenesis and little is known about its role in the development of bone disease in primary biliary cirrhosis (PBC), characterised by low bone formation. Therefore, we have assessed the circulating levels and the liver expression of sclerostin in this cholestatic disease. Serum sclerostin levels were measured in 83 women with PBC (mean age: 60±12 years) and 101 control women. Lumbar and femoral BMD as well as parameters of mineral metabolism and bone remodeling were measured. Moreover, sclerostin gene expression in the liver was assessed in samples of liver tissue taken by biopsy in 11 PBC patients and 5 healthy controls by real time PCR, and presence and distribution of sclerostin was evaluated in liver slices from 11 patients by immunohistochemistry. The presence and severity of histologic lesions were assessed semiquantitatively in the same liver samples. 77% of patients had low BMD (22% osteoporosis and 55% osteopenia). PBC patients had higher serum sclerostin levels and the liver expression of sclerostin in this cholestatic disease. Serum sclerostin levels were measured in 83 women with PBC, thus suggesting that sclerostin influences the decreased bone formation in this cholestatic disease.

Disclosure: The authors declared no competing interests.
The optimal management strategy for Paget’s disease of bone (PDB) remains to be established although recent clinical guidelines have suggested that bisphosphonates should be given to maintain alkaline phosphatase (ALP) concentrations within the mid reference range. We report upon the long term outcome of treatment in PDB within the PRISM-extension with Zoledronic acid study (PRISM-EZ) in which 502 PDB patients, who all participated in the PRISM study, were followed for an additional 3 years. There were two treatment groups; symptomatic therapy (n=232) where bisphosphonates were only given if symptoms were present and intensive therapy (n=270) where bisphosphonates were given with the aim of maintaining ALP within the reference range. Zoledronic acid was the bisphosphate of choice in the intensive group. Mean concentrations of ALP were in the mid-reference range in the intensive group throughout the study (mean ± SD normalised ALP = 0.71±0.30) but at the upper end of the reference range in the symptomatic group (1.01±0.81; p<0.001 between groups). There was no significant difference between treatment groups in bone pain and quality of life scores assessed by the SF36 questionnaire. Thirty-eight patients suffered a fracture (23 in the intensive and 15 in the symptomatic treatment groups, respectively). Six out of the above 38 patients had fracture of bone affected by PDB. Sixteen patients required orthopaedic surgery. Patients randomised to receive intensive bisphosphonate therapy were more likely to experience a fracture or undergo orthopaedic surgery than those in the symptomatic arm (Hazard ratio 1.94, 95% CI 1.07-3.51, p=0.029) and this remained significant after correction for baseline characteristics (HR 1.85, 95% CI 1.02-3.38, p=0.044). We conclude that intensive bisphosphonate therapy confers no benefit in patients with PDB and on the contrary may be harmful. Treatment should be directed at patient symptoms rather than keeping ALP concentrations within the reference range.

Disclosure: Stuart HRalston acts as a consultant for Novartis and Merck on behalf of his institution, the University of Edinburgh. William D Fraser acts as a consultant for Procter & Gamble, MSD, Novartis, Sanofi Aventis, Nycomed and Roche. The remaining authors have no interests to declare.

The PRISM-EZ study was supported by a grant from Arthritis Research UK.

**HT3**

Intensive Bisphosphonate Therapy Increases the Risk of Fracture and Requirement for Orthopaedic Surgery in Paget’s Disease: the PRISM-EZ Study

Adrian Tan1, Jemma Hudson2, Allan Walker3, William Fraser4, Graeme MacLennan2, Stuart Ralston1,3

1Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK, 2Health Services Research Unit, University of Aberdeen, Aberdeen, UK, 3Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK, 4Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

**HT4**

Inhibition of Vascular Calcification by Extracellular Nucleotides, P2 Receptors and NPP1

Isabel Orriss1, Dongxing Zhu2, Neil Mackenzie2, Mark Hajjawi3, Jose-Luis Millan4, Timothy Arnett5, Vicky MacRae2

1Royal Veterinary College, London, UK, 2The Roslin Institute, Edinburgh, UK, 3University College London, London, UK, 4Sanford-Burnham Medical Research Institute, La Jolla, USA

Vascular calcification (VC) shares some similarities to skeletal mineralisation, and involves hydroxyapatite deposition in arteries and cardiac muscle. Whilst VC has severe clinical consequences, the cellular mechanisms responsible are not fully elucidated. ATP and UTP (≥1μM) inhibited bone mineralisation via P2 receptor-dependent (P2R) and independent mechanisms. The latter involves the hydrolysis of extracellular nucleotides by NPP1 to produce pyrophosphate (PPi), a key mineralisation inhibitor. This study investigated whether extracellular nucleotides also regulate VC. Vascular smooth muscle cells (VSMCs) were cultured in calcifying medium containing 2.5 mM phosphate for 14 days. We found that VSMCs express multiple P2Rs and expression was up-regulated in calcifying conditions. The key source of extracellular ATP is controlled release from cells: removal of endogenous ATP by apyrase (an ecto-nucleotidase which hydrolyses ATP) resulted in a 45% increase in VSMC calcification. Culture with exogenous ATP and UTP (≥1 μM) decreased VSMC calcification by ≤80% and 90%, respectively (p<0.001). The selective agonists, 2-thioUTP and MRS2768, also inhibited VSMC calcification by ≤70% (p<0.001) suggesting a role for the P2Y2R in mediating these effects. Furthermore, the level of calcification is increased 2-fold in VSMCs from P2Y2R knockout mice. VC is associated with increased VSMC apoptosis and a transdifferentiation of VSMCs towards the osteogenic lineage. We observed that ATP/UTP increased VSMC number and decreased the expression of genes associated with osteoblast differentiation (e.g. Runx2, osterix, Ocn). CTP and GTP (≥10μM), which are not P2R agonists but are hydrolysed by NPP1 to produce pyrophosphate (PPi), inhibited VSMC calcification by ≤70%. Furthermore, in NPP1 knockout VSMCs, the inhibitory actions of ATP and UTP were 10-fold less potent. These results indicate the P2R-independent mechanisms (involving PPi) contribute significantly to the inhibitory actions of extracellular nucleotides on VC. Taken together, our data suggest an important role for extracellular nucleotides, the P2Y2R and NPP1 in the regulation of VC.

Disclosure: The authors declared no competing interests.

This work was supported by Arthritis Research UK (#19205).

**HT5**

Abstract not available
HT6
High Periostin Levels in Cortical Bone of Cathepsin K Knock-Out Mice are Responsible for Increased Periosteal Bone Formation and Bone Mass
Nicolas Bonnet¹, Le Duong², Serge Ferrari¹
¹Service of Bone Diseases, University Geneva Hospital (HUG), Faculty of Medicine (UNIGE), Geneva, Switzerland, ²Merck & Co., NJ, USA

Cathepsin K (CatK) inhibition in preclinical models results not only in lower bone resorption but also in higher bone formation (BF) on both remodeling and modeling surfaces. The mechanisms for greater BF at modeling surfaces remain unexplained. In vitro data suggest that periostin is proteolytically degraded by CatK. Periostin (Postn) is a matricellular protein expressed in the periosteum and osteocytes that mediates β-catenin signalling and skeletal response to loading. We hypothesised that higher BF in Ctsk⁻/⁻ mice might be related to increased periostin expression. For this purpose, BMD, microstructure and histomorphometry were evaluated in the progeny of a Postn⁺/+;X Ctsk⁺/- mouse cross. Postn immunostaining was more intense in Ctsk⁻/⁻ osteocytes and periosteum surfaces vs WT. Postn⁺/+;Ctsk⁻/⁻ have higher BMD, BV/TV, CtBV, CtTh, whereas Postn⁻/-;Ctsk⁺/+ have lower femoral BMD, CtBV, and CtTh compared to WT. Postn⁺/+;Ctsk⁻⁻ have higher Ps-MAR and –BFR (+58% and +137% vs WT, p<0.05), as well as Ec-MAR (+74% vs WT, p<0.05) but lower Ec-MPm/BPm (-40% vs WT, p<0.05), indicating that BF is increased on both cortical envelopes and independently of remodeling surfaces. Removing both Postn alleles in Ctsk⁻/⁻ mice, i.e. Postn⁻/-;Ctsk⁻⁻, prevented the increase in CtBV and Ps-BFR, but had no effect on Ec-MPm/BPm which remained low (-51% vs WT, p<0.05), indicating that Postn mediates cortical bone formation but has no influence on CatK dependent bone remodeling. In contrast, trabecular microarchitecture at the distal femur and vertebrae was not affected by Postn deletion in Ctsk⁻/⁻ mice, indicating that Postn-dependent bone formation in these mice occurs specifically at cortical surfaces. In conclusions, periostin expression is increased in Ctsk⁻/⁻ mice and is responsible for the increased modeling-based bone formation observed on cortical bone in the absence of cathepsin K.

Disclosure: This work was supported by MSD.